BRAF and malignant colon neoplasm: It has been shown that BRAF mutation is observed more frequently in right-sided colon cancer than in left-sided colon cancer, which might partly explain the higher response rate to cetuximab in patients with left-sided colon cancer observed in other studies [32, 33].